Latest news with #BajajHealthcare
Business Standard
6 hours ago
- Business
- Business Standard
Bajaj Healthcare slides after WTD Dhananjay Sabaji Hatle resigns
Bajaj Healthcare fell 1.94% to Rs 527.50 after the company informed that Dhananjay Sabaji Hatle, whole-time director (WTD) of the company, has tendered his resignation with immediate effect. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. Bajaj Healthcare reported standalone net profit of Rs 11.18 crore in Q4 FY25 as compared with net loss of Rs 29.92 crore posted in Q4 FY24. However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025.
&w=3840&q=100)
Business Standard
27-05-2025
- Business
- Business Standard
Bajaj Healthcare slips 9% on weak Q4 operational performance; details here
Bajaj Healthcare share price: Pharmaceutical company Bajaj Healthcare share price was under pressure on Tuesday, May 27, 2025, with the scrip dropping up to 8.67 per cent to hit an intraday low of ₹550. At 10:40 AM, Bajaj Healthcare shares continued to trade near day's low level, down 7.51 per cent lower at ₹557 per share. In comparison, BSE Sensex was trading 0.99 per cent lower at 81,360.50 level. Why did Bajaj Healthcare share price fall? Bajaj Healthcare share price dropped today on the back of weak operational performance in the March quarter of FY25 (Q4FY25). The company's earnings before interest, tax, depreciation and amortisation (Ebitda) fell 26.7 per cent year-on-year (Y-o-Y) to ₹11.75 crore in the March quarter of FY25, from ₹16.02 crore in the March quarter of FY24. Ebitda margin contracted to 7.61 per cent in Q4FY25, from 11.97 per cent a year ago (Q4FY24). On the brighter side, the company's profit, or bottom line, came in at ₹11.17 crore, as against a loss of ₹29.92 crore a year ago. Bajaj Healthcare dividend Bajaj Healthcare Board of Directors has recommended a final dividend of 20 per cent i.e. ₹1 per equity share on face value of ₹5 each for FY25, subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company. About Bajaj Healthcare Bajaj Healthcare, established in 1993, is a among the leading Indian manufacturers specialising in bulk drugs and active pharmaceutical ingredients (APIs). The company develops and supplies a broad portfolio of APIs such as ascorbic acid, citicoline sodium, and carbamazepine, catering to the pharmaceutical, nutraceutical, and food industries. Their commitment to quality and innovation extends to the nutraceutical space as well, with products like Inositol Nicotinate and Magnesium L-Threonate forming part of their specialised offerings. With a strong focus on cost-effectiveness, consistent quality, and timely delivery, Bajaj Healthcare has built a solid global presence. Its customer base spans across international markets, reflecting the company's ability to meet global regulatory standards and diverse client needs.
Business Standard
27-05-2025
- Business
- Business Standard
Bajaj Healthcare reports standalone net profit of Rs 11.18 crore in the March 2025 quarter
Sales rise 15.36% to Rs 154.47 crore Net profit of Bajaj Healthcare reported to Rs 11.18 crore in the quarter ended March 2025 as against net loss of Rs 29.92 crore during the previous quarter ended March 2024. Sales rose 15.36% to Rs 154.47 crore in the quarter ended March 2025 as against Rs 133.90 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 39.50 crore in the year ended March 2025 as against net loss of Rs 83.79 crore during the previous year ended March 2024. Sales rose 14.61% to Rs 542.60 crore in the year ended March 2025 as against Rs 473.42 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 154.47133.90 15 542.60473.42 15 OPM % 7.6211.98 - 15.1916.11 - PBDT 19.2616.48 17 73.9355.27 34 PBT 11.739.18 28 46.0127.65 66 NP 11.18-29.92 LP 39.50-83.79 LP
Business Standard
27-05-2025
- Business
- Business Standard
Bajaj Healthcare reports turnaround Q4 numbers
Bajaj Healthcare reported standalone net profit of Rs 11.18 crore in Q4 FY25 as compared with net loss of Rs 29.92 crore posted in Q4 FY24. However, revenue from operations jumped 15.36% year-on-year (YoY) to Rs 154.47 crore in the quarter ended 31 March 2025. The company reported a profit before tax of Rs 11.72 crore in Q4 FY25, compared to a pre-tax loss of Rs 35.15 crore in the corresponding quarter of the previous year. Total expenses increased by 19.17% YoY to Rs 156.32 crore in Q4 FY25. Cost of material consumed was Rs 100.49 crore (up 98.47% YoY), while employee expenses stood at Rs 15.71 crore (up 47.92% YoY) and finance costs came in at Rs 6.08 crore (up 1.16% YoY) during the period under review. On a full-year basis, the company reported a standalone net profit of Rs 39.50 crore in FY25, as against a net loss of Rs 83.79 crore in FY24. Revenue from operations jumped 14.61% YoY to Rs 542.60 crore in FY25. Meanwhile, the companys board has recommended a final dividend of Rs 1 per equity share for the financial year 2024-25, subject to the approval of the shareholders at the ensuing Annual General Meeting of the company. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara, Gujarat; one manufacturing plant of finished formulations in Vadodara, Gujarat; and one manufacturing plant of intermediates in Tarapur, Maharashtra. The counter tumbled 7.75% to Rs 555.60 on the BSE.
Business Standard
16-05-2025
- Business
- Business Standard
India Ratings revises rating outlook of Bajaj Healthcare to 'stable'; affirms rating at 'A-
Bajaj Healthcare (BHL) said that India Ratings and Research has revised the outlook on the company's bank facilities to 'stable' from 'negative' while affirming the ratings at 'IND A-'. The agency has affirmed the companys short-term rating at 'IND A2+. India Ratings and Research stated that the outlook revision reflects strong growth in BHLs revenue and profitability in 9MFY25, coupled with the equity infusions during FY25-FY26 through preferential equity share allotment and share warrants, leading to the repayment of debt and funding for capex requirements. India Ratings notes the equity infusions have led to a significant improvement in the companys credit metrics, with its leverage remaining below 2x over the near to medium term. The ratings reflect BHLs improving business mix, led by diversification in higher margin business formulations coupled with revenue emanating from contract development and manufacturing organisation (CDMO) business which has a long term visibility of supplies and profitability. The agency notes although active pharmaceutical ingredient (API) pricing has stabilised, competition from China in its key products will continue to remain a monitorable. As per the management, BHL has backward integration in its large molecules which will offset any further pricing challenges. The agency will monitor the improvement in the working capital cycle and its impact on the credit metrics in the near term. India Ratings further said that a significant increase in the scale of operations and the profitability while improving the gross working capital cycle, resulting in the net leverage reducing below 2.0x, on a sustained basis, could lead to a positive rating action. However, a significant decline in the scale of operations and the EBITDA margins, along with deterioration in the gross working capital cycle, liquidity position and overall credit metrics, with the net leverage remaining above 3.0x, all on a sustained basis, will be negative for the ratings. Bajaj Healthcare manufactures APIs and branded and generic formulations. It has five API manufacturing plants, located in Tarapur, Maharashtra, and Vadodara in Gujarat: one manufacturing plant of finished formulations in Vadodara, Gujarat and one manufacturing plants of intermediates in Tarapur, Maharashtra. The scrip shed 0.86% to currently trade at Rs 553.60 on the BSE.
